Peanut Allergy (CNP-201)

CNP-201 is a biodegradable nanoparticle encapsulating peanut protein. It has the potential to treat patients with peanut allergy by reducing the need for strict peanut avoidance and reducing the potentially fatal health risks associated with peanut allergy.

COUR filed an IND for CNP-201 in December 2020 and plans to begin a first-in-human study in
Q1 2021.